Recursion Pharmaceuticals Inc (OQ:RXRX)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 41S Rio Grande Street
SALT LAKE CITY UT 84101
Tel: N/A
Website: https://www.recursion.com
IR: See website
<
Key People
Tina Marriott Larson
President, Chief Operating Officer
Christopher Gibson
Chief Executive Officer, Director
Michael Secora
Chief Financial Officer
David J. Mauro
Chief Medical Officer
   
Business Overview
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.
Financial Overview
For the fiscal year ended 31 December 2023, Recursion Pharmaceuticals Inc revenues increased 12% to $44.6M. Net loss increased 37% to $328.1M. Revenues reflect Grant revenue increase from $162K to $699K. Higher net loss reflects Research & Development Expense - Balanci increase of 42% to $186.4M (expense), Stock-based Compensation in R&D increase from $10.1M to $22M (expense), Stock-Based Compensation increase of 73% to $24.4M (expense).
Employees: 500 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $1,709M as of Dec 31, 2023
Annual revenue (TTM): $44.58M as of Dec 31, 2023
EBITDA (TTM): -$324.31M as of Dec 31, 2023
Net annual income (TTM): -$328.07M as of Dec 31, 2023
Free cash flow (TTM): -$299.74M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 237,617,203 as of Apr 12, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.